Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?
Another sudden reversal for high-flying artificial-intelligence stocks sent Wall Street reeling
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.12%. June E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26...
British pharmaceutical giant GlaxoSmithKline (GSK) is buying cancer drugmaker Nuvalent (NUVL) for $10.6 ...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...
New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026
Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC